Open AccessDiagnostic value of platelet‐lymphocyte ratio and hemoglobin‐platelet ratio in patients with rectal cancer
Author(s) -
Mo Cuiju,
Hu Zuojian,
Qin Shanzi,
Chen Huaping,
Huang Li,
Li Shan,
Cao Zhao
Publication year - 2020
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23153
Subject(s) - medicine , carcinoembryonic antigen , colorectal cancer , gastroenterology , platelet , receiver operating characteristic , lymphocyte , cancer , neutrophil to lymphocyte ratio , metastasis , area under the curve , lymph node metastasis , oncology
Background This study aimed to investigate the diagnostic value of platelet‐lymphocyte ratio (PLR) and hemoglobin‐platelet ratio (HPR) combined or not with carcinoembryonic antigen (CEA) in rectal cancer. Methods We recruited 235 patients pathologically diagnosed with rectal cancer, 113 patients with benign rectal diseases, and 229 healthy control patients in this retrospective analysis. Then, the correlation between PLR, HPR, and clinicopathological findings was analyzed. Receiver operating characteristic (ROC) curve was used to assess the diagnostic value of PLR and HPR combined or not with CEA in rectal cancer patients. Results The levels of PLR, HPR, and CEA were higher in rectal cancer patients than those in the subjects with benign rectal diseases ( P < .001) and the healthy controls ( P < .001). Platelet‐lymphocyte ratio and HPR were associated with lymph node metastasis and tumor stage, rather than serosa invasion, distant metastasis, or tumor size. PLR or HPR combined with CEA produced larger area under curve (AUC) (AUC PLR+CEA = 0.75, 95% CI = 0.70‐0.79, AUC HPR+CEA = 0.76, 95% CI = 0.71‐0.80) than PLR ( P < .0001), HPR ( P < .0001), or CEA ( P = .024) alone. Conclusion Our results suggest that PLR or HPR combined with CEA can increase diagnostic efficacy and may be a useful diagnostic marker for patients with rectal cancer.